Jack is a co-founder and Vice President of Discovery Chemistry at Kimia Therapeutics, joining the company in April, 2023, bringing over 14 years of experience advancing a range of innovative platform chemistry technologies from ideation to application in drug discovery. At Kimia, Jack leads the development and implementation of novel nanoliter-scale chemistries for hit identification via Kimia’s core platform technology, ATLAS. For over 25 years, Jack’s research focus in academia and industry has been the development of novel, but practical chemical approaches to address unmet challenges in drug discovery. He began his professional career at Carmot Therapeutics in 2011, contributing at an early stage of the company to the development of the Chemotype Evolution platform, which led ultimately to the development of clinical-stage drug candidates resulting in acquisition of the company by Roche in 2023. In 2013, Jack joined the Protein Chemistry department at Genentech wherein he came to lead the bioconjugation chemistry group, focusing on antibody-drug conjugates (ADCs) and other drug delivery systems. His efforts resulted in the advancement of several ADCs and bioconjugates to the development stage and early-phase clinical trials as well as innovative applications of bioconjugation chemistry, including antibody-mediated delivery of degraders and bioorthogonally-activated prodrugs. Following Genentech, Jack rejoined Carmot Therapeutics in 2021 as Principal Investigator in Discovery Chemistry, further advancing Chemotype Evolution, before co-founding Kimia.

Jack holds a PhD in Chemistry from the University of Wisconsin – Madison and has conducted post-doctoral training at UCSF. His academic work includes a Fulbright Fellowship carried out at the University of Leipzig in Germany.

‍